Abstract: Objective To observe the clinical efficacy and safety of paliperidone palmitate in treatment of 200 cases of young and middle-aged patients with schizophrenia. Methods All patients were divided into research group (paliperidone palmitate) and control group (risperidone) in accordance with registration order. The whole treatment cycle lasted for 24 weeks. Psychotic symptoms, quality of life, social function and drug safety were tested respectively at these time points, including before treatment, treatment of 1, 4, 8, 16, 24 weeks. The positive and negative symptoms scale (PANSS), clinical global impression-severity (CGI-S), personal and social performance scale (PSP) and treatment emergent symptom scale (TESS) were regarded as the evaluation indicators. Results 200 patients participated in the study, 191 cases finished the research, 96 cases in paliperidone palmitate group, 95 cases in risperidone group. Before treatment, PANSS, CGI-S and PSP showed no significant difference between two groups. After 24-week treatment, PANSS and TESS were improved, but the comparative differences between two groups were not meaningful. CGI-S and PSP were improved at each time point of treatment, and improvement was more obvious in paliperidone palmitate group. Meanwhile, differences between two groups were statically significant (P<0.05). Conclusion Paliperidone palmitate, which has few adverse drug reactions, can effectively improve the symptoms of the youth patients with schizophrenia, and enhance their social function.

Key words: paliperidone, palmitate,risperidone,schizophrenia,drug, safety,social, function